Risk Disclosure

• AI-assisted medical decisions are supplementary tools and do not replace professional medical judgment

• Virtual nursing systems may experience technical failures requiring immediate human intervention

• Diagnostic accuracy depends on data quality and may vary across patient populations

• Telemedicine consultations have inherent limitations compared to in-person examinations

• Patient safety protocols require continuous human oversight despite AI automation

• Medical device malfunctions could result in delayed or incorrect treatment recommendations

• FDA approval processes for AI medical devices are evolving and may change requirements

• HIPAA compliance failures could result in significant fines and legal liability

• State medical licensing requirements may limit telemedicine service areas

• Reimbursement policies for AI-assisted care are subject to change by CMS and private insurers

• International expansion requires compliance with varying healthcare regulations

• Blockchain-based credentialing systems must meet state medical board requirements

• Florida Statute 381.986 requires stem cell clinics to register with the Department of Health

• Only minimal manipulation of autologous stem cells is permitted without FDA approval

• Advertising restrictions prohibit claims of curing specific diseases without clinical evidence

• Informed consent must include disclosure that stem cell treatments may not be FDA-approved

• Practitioners must be licensed physicians with appropriate training and credentials

• Violations can result in disciplinary action, fines up to $10,000 per violation, and criminal penalties

• Florida law requires disclosure that stem cell therapies are considered investigational

• Insurance coverage for stem cell treatments is limited and often not reimbursed

• FDA regulates stem cells as biological products under 21 CFR Part 1271

• Stem cell products requiring more than minimal manipulation need FDA approval (BLA)

• Homologous use requirement: cells must perform same function in recipient as in donor

• Federal enforcement actions can include warning letters, injunctions, and criminal prosecution

• Medicare and Medicaid generally do not cover investigational stem cell treatments

• False or misleading claims violate FTC Act and can result in federal prosecution

• Clinical trials require IND (Investigational New Drug) application approval

• Interstate commerce of unapproved stem cell products is prohibited

• Texas Medical Board Rule 197.3 requires informed consent for stem cell procedures

• Physicians must disclose FDA approval status and evidence of safety/efficacy

• Texas law prohibits deceptive trade practices in marketing stem cell treatments

• Stem cell clinics must comply with Texas Health and Safety Code Chapter 162

• Advertising must not guarantee results or claim to cure specific diseases

• Patient records must document medical necessity and treatment rationale

• Texas Medical Board can discipline physicians for unprofessional conduct

• Civil liability exposure for adverse outcomes from stem cell treatments

Not Medical Advice

Information provided by Royal Ponciana MedTech's AI systems and telemedicine platforms does not constitute medical advice and should not be relied upon as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information provided by our systems.

Not Investment Advice

Nothing on this website or in our documentation constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the website's content as such. Royal Ponciana MedTech does not recommend that any cryptocurrency or token should be bought, sold, or held by you. Conduct your own due diligence and consult your financial advisor before making any investment decisions. Tokens are offered only to accredited investors as defined by SEC regulations.

Forward-Looking Statements

This website and associated documents contain forward-looking statements regarding future events, business plans, and financial projections. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Regulatory Compliance

Royal Ponciana MedTech operates in a highly regulated industry. We strive to comply with all applicable federal, state, and local regulations including but not limited to FDA, HIPAA, FTC, SEC, and state medical board requirements. However, regulatory landscapes are constantly evolving, and we cannot guarantee that our operations will remain compliant with all future regulatory changes. Users and investors assume all risks associated with regulatory uncertainty.